InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,882.29
(
2.18%
)
Post# of 252498
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119983
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 161010

Friday, 05/10/2013 4:30:53 PM

Friday, May 10, 2013 4:30:53 PM

Post# of 252498
Sounds like you’re blaming XOMA’s current management for the disclosures that XOMA’s former management did not make about AEs in the Gevokicumab diabetes trials. I suppose current management could release those data, but it’s not typical for a biotech company to focus investors’ attention—even indirectly—on defunct programs such as Gevokizumab for diabetes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up